RxDoctor Payments Data

Diana Leszczewicz, APRN

Family · Elkton, KYNPI 1770129272

Payments from drug & device makers

$1,623in general payments, 2019–2025

Across 100 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$435
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$186
  • Corium, LLC$148
  • Lilly USA, LLC$122
  • Otsuka America Pharmaceutical, Inc.$108
  • Novo Nordisk$91
  • plus $533 from 15 others

What the payments were for

  • Food & beverage$1,623100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,623 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$536
Medicare patients
15
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$66,922
JardianceEmpagliflozin33$29,279
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$25,146
MounjaroTirzepatide19$19,915
EliquisApixaban25$15,683
FarxigaDapagliflozin Propanediol18$14,735
JanuviaSitagliptin Phosphate22$13,174
EntrestoSacubitril/Valsartan16$12,102
XareltoRivaroxaban11$7,241
Albuterol Sulfate HfaAlbuterol Sulfate103$3,553
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,070
Gabapentin126$1,729
Atorvastatin Calcium181$1,285
Pregabalin13$1,235
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen42$947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$91$66,92258 claims
Lilly USA, LLCMounjaro$122$19,91519 claims
PfizerEliquis$62$15,68325 claims
AstraZenecaFarxiga$47$14,73518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Elkton

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →